Biotech Stock Crashes As FDA Hits It With A Clinical Hold On Safety Issues In Mice

Biotech stock Protagonist Therapeutics (PTGX) crashed Friday after the Food and Drug Administration placed its key drug on hold due to safety questions.


Protagonist is studying the drug, rusfertide, in patients with blood diseases. But mice who received the drug developed tumors under their skin. Now, the FDA says Protagonist must stop all human studies of rusfertide.

In morning trading on today’s stock market, the biotech stock plummeted 57.2% near 19.80.

SVB Leerink analyst Joseph Schwartz expected the biotech stock to dive.

“Considering that rusfertide accounts for the majority of Protagonist’s stock price by our estimation, we expect shares to trade down substantially on the news today,” he said in a note to clients. “However, in our view, not all this value should come out of the stock, as these holds are usually resolved.”

Biotech Stock Crashes On Hold

But Protagonist may struggle hitting its timeline, Schwartz said. The company is submitting safety reports to the FDA, updating investigator and patient documents, and modifying the study protocols.

Investors in the biotech stock were expecting Protagonist to have proof-of-concept data for rusfertide in hereditary hemochromatosis in the second half of 2021, Schwartz said. Plus, investors were hoping for Phase 2 results in polycythemia vera in the fourth quarter.

Still, he kept his outperform rating on the biotech stock.

The biotech stock fell to its lowest point since January. Shares fell well below their 200-day moving average, according to

Bullishly, biotech stock Protagonist also has a strong Relative Strength Rating of 95, IBD Digital shows. This puts shares in the leading 5% of all stocks in terms of 12-month performance.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


The FDA Is Likely To Sign Off On Covid Boosters — With Some Caveats For Pfizer, Moderna

Why The Future Is Cloudy For This Aerie Pharmaceuticals Drug As Shares Plummet

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Profit From Short-Term Trends With SwingTrader

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button